ArticleTheranostics2025

A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment.

Lei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.